Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct

Cited by (348)

Items 101–200 of 348

1. Intimate Cell Conjugate Formation and Exchange of Membrane Lipids Precede Apoptosis Induction in Target Cells during Antibody-Dependent, Granulocyte-Mediated Cytotoxicity
   Heike Horner, Carola Frank, Claudia Dechant, Roland Repp, Martin J. Glennie, Martin Herrmann i, Bernhard Stockmeyer · 2007 · The Journal of Immunology
2. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
   Julia Stieglmaier, Jonathan Benjamin, Dirk Nagorsen · 2015 · Expert Opinion on Biological Therapy
3. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia
   Hervé Dombret, Max S. Topp, Andre C. Schuh, Andrew H. Wei, Simon Durrant, Christopher Larry Bacon, Qui Tran, Zachary F. Zimmerman, Hagop M. Kantarjian · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
4. Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release
   Maria Amann, Sandrine d’Argouges, Grit Lorenczewski, Klaus Brischwein, Roman Kischel, Ralf Lutterbuese, Susanne Mangold, Doris Rau, Jörg Volkland, Stefan Pflanz et al. · 2009 · Journal of Immunotherapy
5. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system
   Claudia Arndt, Anja Feldmann, Malte v. Bonin, Marc Cartellieri, E-M Ewen, Stefanie Koristka, Irene Michalk, Slava Stamova, Nicole Berndt, Anne Gocht et al. · 2013 · Leukemia
6. No free rides: management of toxicities of novel immunotherapies in ALL, including financial
   Tania Jain, Mark Robert Litzow · 2018 · Hematology
7. Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents
   Jiang, Xiling, Chen, Xi, Carpenter, Thomas J., Wang, Jun, Zhou, Rebecca, Davis, Hugh M., Heald, Donald L., Wang, Weirong · 2018 · mAbs
8. No free rides: management of toxicities of novel immunotherapies in ALL, including financial
   Tania Jain, Mark Robert Litzow · 2018 · Blood Advances
9. Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap
   Anthony Longhitano, Monica A. Slavin, Simon James Harrison, Benjamin W. Teh · 2021 · Blood Reviews
10. Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6
    Christiane Stadler, Hayat Bähr-Mahmud, Laura M. Plum, Kathrin Schmoldt, Anne C. Kölsch, Özlem Türeci, Uğur Şahin · 2015 · OncoImmunology
11. CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice
    Lucas A. Horn, Nicholas G. Ciavattone, Ryan S. Atkinson, Netsanet Woldergerima, Julia Wolf, Virginia K. Clements, Pratima Sinha, Munanchu Poudel, Suzanne Ostrand‐Rosenberg · 2017 · Oncotarget
12. The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia
    Jonathan E. Benjamin, Anthony Selwyn Stein · 2016 · Therapeutic Advances in Hematology
13. World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA
    Eugen Dhimolea, Janice M. Reichert · 2012 · mAbs
14. Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection
    Guido Ferrari, Barton F. Haynes, Scott Koenig, Jeffrey L. Nordstrom, David M. Margolis, Georgia D. Tomaras · 2016 · Nature Reviews Drug Discovery
15. Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3
    Bernd Schlereth, Petra Kleindienst, Iduna Fichtner, Grit Lorenczewski, Klaus Brischwein, Sandra Lippold, Antônio da Silva, Mathias Locher, Roman Kischel, Ralf Lutterbüse et al. · 2005 · Cancer Immunology Immunotherapy
16. Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Anthony Selwyn Stein, Janet L. Franklin, Victoria M. Chia, Deborah Arrindell, William N. Kormany, Jacqueline Wright, Mandy Parson, Hamid R. Amouzadeh, Jessica Choudhry, Guiandre L. Joseph · 2018 · Drug Safety
17. Novel immunotherapies for hematologic malignancies
    Michelle Hase Nelson, Chrystal Mary Paulos · 2014 · Immunological Reviews
18. Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer
    Philippe Fournier, Volker Schirrmacher · 2012 · BioDrugs
19. Antibody-Based Cancer Therapy
    Djoke Hendriks, Goda Choi, Marco de Bruyn, Valerie R. Wiersma, Edwin Bremer · 2017 · International review of cytology
20. The old CEACAMs find their new role in tumor immunotherapy
    Zi-Wen Han, Zhi-Wu Lyv, Bin Cui, Yingying Wang, Jun-Ting Cheng, Ying Zhang, Wen-Qi Cai, Yang Zhou, Zhaowu Ma, Xian-Wang Wang et al. · 2020 · Investigational New Drugs
21. Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy
    Zachary Franklin Zimmerman, Tapan N. Maniar, Dirk Nagorsen · 2014 · International Immunology
22. Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
    Mojtaba Akhtari, Kum‐Ja Lee, Ashley Weissman, Vivian Chow, Sunil Tulpule · 2016 · Therapeutics and Clinical Risk Management
23. Antibody-based therapies in patients with acute lymphoblastic leukemia
    Shira Naomi Dinner, Michaela Liedtke · 2018 · Hematology
24. Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond
    Anna Aureli, Beatrice Marziani, Adriano Venditti, Tommaso Sconocchia, Giuseppe Sconocchia · 2023 · Cancers
25. “NextGen” Biologics: Bispecific Antibodies and Emerging Clinical Results
    Archana B. Thakur, Lawrence G. Lum · 2016 · Expert Opinion on Biological Therapy
26. Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
    Dain Moon, Nara Tae, Yunji Park, Seung‐Woo Lee, Dae Hee Kim · 2022 · Immune Network
27. Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?
    Kavina Shah, Maria José Leandro, Mark Steven Cragg, Florian Kollert, Franz Schuler, Christian Klein, Venkat R Reddy · 2024 · Clinical & Experimental Immunology
28. Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics
    Cris Kamperschroer, Jacintha M. Shenton, Herve N. Lebrec, John K. Leighton, Paul A. Moore, Oliver Thomas · 2020 · Journal of Immunotoxicology
29. Multifunctional receptor-targeting antibodies for cancer therapy
    Yanni Zhu, Sung Hugh Choi, Khalid Shah · 2015 · The Lancet Oncology
30. Simultaneous targeting of prostate stem cell antigen and prostate‐specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell‐retargeting system
    Claudia Arndt, Anja Feldmann, Stefanie Koristka, Marc Cartellieri, Maria Dimmel, Armin Ehninger, Gerhard Ehninger, Michael Philipp Bachmann · 2014 · The Prostate
31. Clinical overview of anti-CD19 BiTE® and ex vivo data from anti-CD33 BiTE® as examples for retargeting T cells in hematologic malignancies
    Gerhard Zugmaier, Matthias Klinger, Margit Schmidt, Marion S. Subklewe · 2015 · Molecular Immunology
32. An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity
    Yik Andy Yeung, Veena Krishnamoorthy, Danielle E. Dettling, Cesar Sommer, Kris Poulsen, Irene Ni, Amber T. Pham, Wei Chen, Sindy Liao-Chan, Kevin C. Lindquist et al. · 2020 · Molecular Therapy
33. Redirected Lysis of Human Melanoma Cells by a MCSP/CD3-bispecific BiTE Antibody That Engages Patient-derived T Cells
    Hitoe Torisu‐Itakura, Hans Francis Schoellhammer, Myung‐Shin Sim, Reiko Furuse Irie, Susanne Hausmann, Tobias Raum, Patrick A. Baeuerle, Donald L. Morton · 2011 · Journal of Immunotherapy
34. Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
    Josep‐María Ribera, Albert Ferrer, Jordi Ribera, Eulàlia Genescà · 2015 · OncoTargets and Therapy
35. Blinatumomab for the treatment of acute lymphoblastic leukemia
    Jason Benjamin Kaplan, Marina Grischenko, Francis Joseph Giles · 2015 · Investigational New Drugs
36. The intriguing options of multispecific antibody formats for treatment of cancer.
    Ulrich H. Weidle, Georg Tiefenthaler, Elisabeth H. Weiss, Guy J. Georges, Ulrich Brinkmann · 2013 · PubMed
37. Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies
    B Rogala, Craig W. Freyer, Evelena P. Ontiveros, Elizabeth A. Griffiths, Eunice S. Wang, Meir Wetzler · 2015 · Expert Opinion on Biological Therapy
38. Bispecific Antibodies for Cancer Therapy
    Nurit Hollander · 2009 · Immunotherapy
39. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab
    Anne Christine Wilke, Nicola Gökbuget · 2017 · Expert Opinion on Drug Safety
40. PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia
    Yizhen Li, Takaya Moriyama, Satoshi Yoshimura, Xujie Zhao, Zhenhua Li, Xu Yang, Elisabeth M. Paietta, Mark Robert Litzow, Marina Y Konopleva, Jiyang Yu et al. · 2022 · Science Advances
41. Blinatumomab for the treatment of B-cell lymphoma
    Eunhye Oak, Nancy L. Bartlett · 2015 · Expert Opinion on Investigational Drugs
42. Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition
    Oladapo Yeku, Thapi Dharma Rao, Ian Laster, A. P. Kononenko, Terence J. Purdon, Pei Wang, Ziyou Cui, Hong Liu, Renier J. Brentjens, David R. Spriggs · 2021 · Frontiers in Immunology
43. Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies
    Mohammad A. Tabrizi, Cherryl B. Funelas, Hamza Suria · 2010 · The AAPS Journal
44. The Dynamics of Interactions Among Immune and Glioblastoma Cells
    Katalin Éder, Bernadette Kálmán · 2015 · NeuroMolecular Medicine
45. T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
    Daisuke Kamakura, Ryutaro Asano, Masahiro Yasunaga · 2021 · Pharmaceuticals
46. Novel targeted therapies in acute lymphoblastic leukemia
    Craig Anthony Portell, Anjali S. Advani · 2013 · Leukemia & lymphoma/Leukemia and lymphoma
47. Concomitant Use of Blinatumomab and Donor Lymphocyte Infusion for Mixed-Phenotype Acute Leukemia: A Case Report With Literature Review
    Seren Durer, Ceren Durer, Madeeha Shafqat, Işın Y. Comba, Saad Ullah Malik, Warda Faridi, Shehroz Aslam, Awais Ijaz, Muhammad Junaid Tariq, Muhammad Asad Fraz et al. · 2019 · Immunotherapy
48. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells
    Dongmei Fan, Wei Li, Yuqi Yang, Xiaolong Zhang, Qing Zhang, Yan Yan, Ming Yang, Jianxiang Wang, Dongsheng Xiong · 2015 · Journal of Hematology & Oncology
49. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor
    Jens Schreiner, Daniela S. Thommen, Petra Herzig, Marina Bacac, Christian Klein, Andreas Roller, Anton Belousov, Victor Levitsky, Spasenija Savic, Wolfgang Moersig et al. · 2015 · OncoImmunology
50. Blinatumomab Pharmacodynamics and Exposure–Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia
    Min Zhu, Andrea Kratzer, Jessica Johnson, Chris Holland, Christian Brandl, Indrajeet Singh, Andreas Wolf, Sameer Doshi · 2017 · The Journal of Clinical Pharmacology
51. A modular and controllable T cell therapy platform for acute myeloid leukemia
    Mohamed-Reda Benmebarek, Bruno Loureiro Cadilha, Monika Herrmann, Stefanie Lesch, Saskia Schmitt, Stefan Stoiber, Abbass Darwich, Christian Augsberger, Bettina Brauchle, Lisa Rohrbacher et al. · 2021 · Leukemia
52. Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site
    Thomas List, Dario Neri · 2012 · mAbs
53. Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
    Miguel J. Franquiz, Nicholas James Short · 2020 · Biologics
54. Bioassay Development for Bispecific Antibodies—Challenges and Opportunities
    Ames C. Register, Somayeh Samadzadeh Tarighat, Ho‐Young Lee · 2021 · International Journal of Molecular Sciences
55. For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
    Kirit Singh, Kelly M. Hotchkiss, Aditya A Mohan, Jessica L. Reedy, John Howard Sampson, Mustafa Khasraw · 2021 · Journal for ImmunoTherapy of Cancer
56. Antibody Expression and Production
    Mohamed Al‐Rubeai · 2011 · Cell engineering
57. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era
    Joyce Wing Yan Mak, Alvin Wing Hin Law, Kimmy Wan Tung Law, Rita Ho, Carmen Ka Man Cheung, Man Fai Law · 2023 · World Journal of Gastroenterology
58. Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma
    Youssef Hijazi, Matthias Klinger, Andrea Kratzer, Benjamin M. Wu, Patrick A. Baeuerle, Peter Kufer, Andreas Wolf, Dirk Nagorsen, Min Zhu · 2018 · Current Clinical Pharmacology
59. Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1hibreast cancer via enhancing immune cells activity
    Ri Hong, Yuhai Zhou, Xiujuan Tian, Lijuan Wang, Xiaoyun Wu · 2017 · International Immunopharmacology
60. Recent advances and novel treatment paradigms in acute lymphocytic leukemia
    Nikolaos Papadantonakis, Anjali S. Advani · 2016 · Therapeutic Advances in Hematology
61. Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs
    Slava Stamova, Stefanie Koristka, Juliane Keil, Claudia Arndt, Anja Feldmann, Irene Michalk, Holger Bartsch, Claudia Christiane Bippes, Marc Schmitz, Marc Cartellieri et al. · 2012 · Antibodies
62. Blinatumomab-induced T cell activation at single cell transcriptome resolution
    Yi Huo, Zhen Sheng, Daniel Lu, Daniel Christian Ellwanger, Chi-Ming Li, Oliver R. Homann, Songli Wang, Hong Mei Yin, Ruibao Ren · 2021 · BMC Genomics
63. Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
    Roa Alsajjan, Warren P. Mason · 2023 · Current Oncology
64. Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy.
    Fatemeh Naddafi, Fatemeh Davami · 2015 · PubMed Central
65. Immunological role and underlying mechanisms of B7‐H6 in tumorigenesis
    Yuxuan Hu, Tian Zeng, Xiao Wei Zheng, Qi-hao Hu, Yukun Li, Xiongjin Tan, Haiyan Yue, Wensong Wang, Hui Tan, Juan Zou · 2020 · Clinica Chimica Acta
66. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody‐based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells
    Claudia Arndt, Anja Feldmann, Katrin Töpfer, Stefanie Koristka, Marc Cartellieri, Achim Temme, Armin Ehninger, Gerhard Ehninger, Michael Philipp Bachmann · 2014 · The Prostate
67. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16
    Lisa M. Pörtner, Kathrin Schönberg, Maryam Hejazi, Daniela Brünnert, Frank Neumann, Lars Galonska, Uwe Reusch, Melvyn Little, Rainer R. Haas, Markus Uhrberg · 2012 · Cancer Immunology Immunotherapy
68. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas
    Marcus P. Watkins, Nancy L. Bartlett · 2018 · Expert Opinion on Investigational Drugs
69. An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma
    Patrick C. Gedeon, Bryan D. Choi, Tiffany R. Hodges, Duane A. Mitchell, Darell D. Bigner, John Howard Sampson · 2013 · Expert Review of Clinical Pharmacology
70. Bispecific CD3/HER2 Targeting FynomAb Induces Redirected T Cell-Mediated Cytolysis with High Potency and Enhanced Tumor Selectivity
    Ulrich Wuellner, Kristina Klupsch, Fabian Buller, Isabella Attinger-Toller, Roger Santimaria, Irène Zbinden, Patricia Henne, Dragan Grabulovski, Julian Bertschinger, Simon Brack · 2015 · Antibodies
71. T cell engagers emerge as a compelling therapeutic modality
    Patrick A. Baeuerle, Karsten Sauer, Ricardo Grieshaber‐Bouyer, Jennifer S. Michaelson · 2025 · The Journal of Experimental Medicine
72. Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia
    Shira Naomi Dinner, Daniel J. Lee, Michaela Liedtke · 2013 · Leukemia & lymphoma/Leukemia and lymphoma
73. Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells
    Claudia C. Roskopf, Todd A. Braciak, Nadja C. Fenn, Sebastian Kobold, Georg H. Fey, Karl‐Peter Hopfner, Fuat S. Oduncu · 2016 · Oncotarget
74. Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110
    Juliane Witthauer, Bernd Schlereth, Klaus Brischwein, Hauke Winter, Ilona Funke, Karl‐Walter Jauch, Patrick A. Baeuerle, Barbara Mayer · 2008 · Breast Cancer Research and Treatment
75. Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection
    Guido Ferrari, Justin Pollara, Georgia D. Tomaras, Barton F. Haynes · 2016 · The Journal of Infectious Diseases
76. Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias
    Kinga Panuciak, Mikołaj Margas, Karolina Makowska, Monika Lejman · 2022 · Cells
77. Cancer Immunotherapies: What the Perioperative Physician Needs to Know
    Robert S. Ackerman, Aaron R. Muncey, Nasrin N. Aldawoodi, Rohini Kotha, Rosemarie E. Garcia Getting · 2022 · Current Oncology Reports
78. A Novel B7-H6–Targeted IgG-Like T Cell–Engaging Antibody for the Treatment of Gastrointestinal Tumors
    Wei Zhang, Aurélie Auguste, Xiaoyun Liao, Christian Walterskirchen, K. H. Bauer, Yu-Hsi Lin, Ling Yang, Farzaneh H. Sayedian, Markus Fabits, Michael M. Bergmann et al. · 2022 · Clinical Cancer Research
79. Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia
    Kaylyn Utley Lyons, Lia Gore · 2024 · Haematologica
80. Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC
    Paul Chauvet, Annalisa Paviglianiti, Myriam Labopin, Hélène Labussière, Nicolas Boissel, Marie Robin, Natacha Maillard, Marie Ouachée-Chardin, Édouard Forcade, Xavier Poiré et al. · 2022 · Bone Marrow Transplantation
81. CD47/SIRPα blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies
    Lijun Xu, Shanlong Wang, Jie Li, Bingyu Li · 2019 · Biochemical and Biophysical Research Communications
82. Immunotherapy in Renal Cell Carcinoma
    Annkristin Heine, Tobias A.W. Holderried, Peter Brossart · 2008 · Immunotherapy
83. Characterization of a Novel Single-Chain Bispecific Antibody for Retargeting of T Cells to Tumor Cells via the TCR Co-Receptor CD8
    Irene Michalk, Anja Feldmann, Stefanie Koristka, Claudia Arndt, Marc Cartellieri, Armin Ehninger, Gerhard Ehninger, Michael Philipp Bachmann · 2014 · PLoS ONE
84. Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
    Mingpeng Fu, Qi He, Zilong Guo, Xiaoran Zhou, Heli Li, Liang Zhao, Hongling Tang, Xiaoqi Zhou, Huifen Zhu, Guanxin Shen et al. · 2019 · Frontiers in Immunology
85. Enhancing the effectiveness of γδ T cells by mRNA transfection of chimeric antigen receptors or bispecific T cell engagers
    Scott A. Becker, Brian G. Petrich, Bing Yu, Kristopher A. Knight, Harrison C. Brown, Sunil S. Raikar, Christopher B. Doering, Harold Trent Spencer · 2023 · Molecular Therapy — Oncolytics
86. A Chemo-enzymatically Linked Bispecific Antibody Retargets T Cells to a Sialylated Epitope on CD43 in Acute Myeloid Leukemia
    Lina Bartels, Greta de Jong, Marijn Aletta Gillissen, Etsuko Yasuda, Veronika Kattler, Camille Bru, Christien Fatmawati, Susan E. van Hal-van Veen, Madalina G. Cercel, Gemma Moiset et al. · 2019 · Cancer Research
87. Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study
    Thananya Inthanachai, Chatikorn Boonkrai, Tanapati Phakham, Trairak Pisitkun, Rattapoom Thaiwong, Vichaya Chuthaphakdikun, Nithidol Sakunrangsit, Vudhiporn Limprasutr, Thanyavi Chinsuwan, Nattiya Hirankarn et al. · 2025 · Journal for ImmunoTherapy of Cancer
88. Cell-associated galectin 9 interacts with cytotoxic T cells confers resistance to tumor killing in nasopharyngeal carcinoma through autophagy activation
    Ngar‐Woon Kam, Cho Yiu Lau, Jeffrey Yan Ho Lau, Xin Dai, Yusi Liang, Syrus Pak Hei Lai, Michael King Yung Chung, Valen Zhuoyou Yu, Wenlan Qiu, Mengsu Yang et al. · 2025 · Cellular and Molecular Immunology
89. CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromes
    Tobias Ruck, Niklas Huntemann, Menekse Öztürk, Stefanie Schreiber, Stefanie Lichtenberg, Lars Masanneck, Christopher Nelke, Hend Ben Moussa, Thomas Ulrych, Marc Seifert et al. · 2025 · Molecular Therapy
90. CAR-Modified Vγ9Vδ2 T Cells Propagated Using a Novel Bisphosphonate Prodrug for Allogeneic Adoptive Immunotherapy
    Yizheng Wang, Linan Wang, Naohiro Seo, Satoshi Okumura, Tae Hayashi, Yasushi Akahori, Hiroshi Fujiwara, Yasunori Amaishi, Sachiko Okamoto, Junichi Mineno et al. · 2023 · International Journal of Molecular Sciences
91. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data
    Talha Badar, Anikó Szabó, Mark Robert Litzow, Madelyn Burkart, Ilana R. Yurkiewicz, Shira Naomi Dinner, Mehrdad Hefazi, Rory Michael Shallis, Nikolai Alexandrovich Podoltsev, Anand Ashwin Patel et al. · 2021 · Bone Marrow Transplantation
92. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis
    Max S. Topp, Anthony Selwyn Stein, Nicola Gökbuget, Heinz‐August Horst, Nicolas Boissel, Giovanni Martinelli, Hagop M. Kantarjian, Monika Brüggemann, Yuqi Chen, Gerhard Zugmaier · 2021 · Cancer Medicine
93. A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy
    Dong Liu, Xuexiu Qi, Xiaoyi Wei, Lijun Zhao, Xuechun Wang, Shuhong Li, Zhidong Wang, Licai Shi, Jiean Xu, Hong Mei et al. · 2022 · Theranostics
94. A next generation mathematical model for the in vitro to clinical translation of T-cell engagers
    David A. Flowers, David M. Bassen, Georgi I. Kapitanov, Diana H. Marcantonio, John M. Burke, Joshua F. Apgar, Alison M. Betts, Fei Hua · 2023 · Journal of Pharmacokinetics and Pharmacodynamics
95. Therapeutic targets and new directions for antibodies developed for ovarian cancer
    Heather J. Bax, Debra Hannah Josephs, Giulia Pellizzari, James F. Spicer, Ana Montes, Sophia N. Karagiannis · 2016 · mAbs
96. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia in first salvage
    Jae‐Ho Yoon, Gi June Min, Sung‐Soo Park, Silvia Park, Sung‐Eun Lee, Byung‐Sik Cho, Ki‐Seong Eom, Hee‐Je Kim, Hee‐Je Kim, Chang‐Ki Min et al. · 2019 · Cancer Medicine
97. Development of a bioassay to detect T-cell-activating impurities for T-cell-dependent bispecific antibodies
    Ho‐Young Lee, Edward Contreras, Ames C. Register, Qiang Wu, Kathleen Abadie, Khristofer Garcia, Pin Yee Wong, Guoying Jiang · 2019 · Scientific Reports
98. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia
    Zheng Shi, Yiqian Zhu, Jing Zhang, Baoan Chen · 2022 · Hematology
99. A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity
    Aruto Sugiyama, Mitsuo Umetsu, Hikaru Nakazawa, Teppei Niide, Tomoko Onodera, Katsuhiro Hosokawa, Shuhei Hattori, Ryutaro Asano, Izumi Kumagai · 2017 · Scientific Reports
100. A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells
     Charlotte U. Brey, Julia Proff, Natascha Teufert, Benjamin Salzer, Johannes Brozy, Markus Münz, Jochen Pendzialek, Armin Ensser, Wolfgang Holter, Manfred Lehner · 2018 · Scientific Reports